Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin

International Journal of Oncology

Volumn 34, Issue 5, 2009, Pages 1353-1362

  Kim, Tae Hyun ^a   Yoo, Young Hyun ^a   Kang, Do Young ^a   Shu, Hongsuk ^b   Park, Moon Ki ^c   Park, Ki Jae ^a   Kim, Sung Heun ^a  

^a Dong A University College of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Daegu Haany University   (South Korea)

Author keywords

Anaplastic thyroid cancer; Apoptosis; Doxorubicin; HS 1200; Lactacystin; Valproic acid

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DEOXYRIBONUCLEASE; DOXORUBICIN; HISTONE DEACETYLASE; HS 1200; LACTACYSTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROCASPASE 7; TRYPTOPHAN; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PHASE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA CONTENT; DRUG POTENTIATION; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME DEGRADATION; HAPLOIDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; THYROID CARCINOMA; WESTERN BLOTTING;

ACETYLCYSTEINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; CELL SURVIVAL; CHENODEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASES; HUMANS; MITOCHONDRIA; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 67649451962     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000262     Document Type: Article

References (48)

1. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403: 41-45, 2000.
2. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E and Eisenman RN: Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89: 349-356, 1997.
3. Verdin E, Dequiedt F and Kasler HG: Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293, 2003.
4. Yoshida M, Hoshikawa Y, Koseki K, Mori K and Beppu T: Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot 43: 1101-1106, 1990.
5. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
6. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749, 2003.
7. Cinatl J Jr, Cinatl J, Dsiever PH, et al: Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8: 958-963, 1997.
8. Kramer OH, Zhu P, Ostendorff HP, et al: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22: 3411-3420, 2003.
9. Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU and Cinatl J: Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 20: 97-106, 2002.
10. Gurvich N, Tsygankova OM, Meinkoth JL and Klein PS: Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086, 2004.
11. Cip1, CDK4, and CMYC. Mol Cancer Ther 4: 1912-1922, 2005.
12. Takai N, Desmond JC, Kumagai T, et al: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004.
13. Im EO, Choi YH, Paik KJ, et al: Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett 163: 83-93, 2001.
14. Pierie JP, Muzikansky A, Gaz RD, Faquin WC and Ott MJ: The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9: 57-64, 2002.
15. Levendag PC, De Porre PM and van Putten WL: Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26: 125-128, 1993.
16. Roh MS, Kim CW, Park BS, et al: Trichostatin A induces apoptosis on human osteosarcoma cells in histone acetylation-and mitochondria-dependent fashions. Apoptosis 9: 583-589, 2004.
17. Zhang XD, Gillespie SK, Borrow JM and Hersey P: The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66: 1537-1545, 2003.
18. Golab J, Stoklosa T, Czajka A, et al: Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res 20: 1717-1721, 2000.
19. Kieslich M, Schwabe D, Cinatl J Jr and Driever PH: Increase of fetal hemoglobin synthesis indicating differentiation induction in children receiving valproic acid. Pediatr Hematol Oncol 20: 15-22, 2003.
20. Warrell RP Jr, He LZ, Richon V, Calleja E and Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998.
21. Graziani G, Tentori L, Portarena I, Vergati M and Navarra P: Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinology 144: 2822-2828, 2003.
22. Mongan NP and Gudas LJ: Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 4: 477-486, 2005.
23. Massart C, Barbet R, Genetet N and Gibassier J: Doxorubicin induces Fas-mediated apoptosis in human thyroid carcinoma cells. Thyroid 14: 263-270, 2004.
24. Rho JH, Kang DY, Park KJ, et al: Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation. Int J Oncol 27: 465-471, 2005.
25. Hofmann AF: Chemistry and enterohepatic circulation of bile acids. Hepatology 4: 4-14, 1984.
26. Martinez JD, Stratagoules ED, LaRue JM, et al: Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 31: 111-118, 1998.
27. Jones B, Roberts PJ, Faubion WA, Kominami E and Gores GJ: Cystatin A expression reduces bile salt-induced apopt in a rat hepatoma cell line. Am J Physiol 275: 723-730, 1998.
28. Martinez-Diez MC, Serrano MA, Monte MJ and Marin JJ: Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. Biochim Biophys Acta 1500: 153-160, 2000.
29. Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD and Gores GJ: The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 275: 20210-20216, 2000.
30. Patel T, Bronk SF and Gores GJ: Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest 94: 2183-2192, 1994.
31. Patel T, Roberts LR, Jones BA and Gores GJ: Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 18: 105-114, 1998.
32. Powell AA, LaRue JM, Batta AK and Martinez JD: Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 356: 481-486, 2001.
33. Kim ND, Im EO, Choi YH and Yoo YH: Synthetic bile acids: novel mediators of apoptosis. J Biochem Mol Biol 35: 134-141, 2002.
34. Choi YH, Im EO, Suh H, Jin Y, Yoo YH and Kim ND: Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett 199: 157-167, 2003.
35. Park SE, Choi HJ, Yee SB, et al: Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells. Int J Oncol 25: 231-236, 2004.
36. Seo SY, Jun EJ, Jung SM, et al: Synthetic chenodeoxycholic acid derivative HS-1200-induced apoptosis of p815 mastocytoma cells is augmented by co-treatment with lactacystin. Anticancer Drugs 14: 219-225, 2003.
37. Jeong JH, Park JS, Moon B, et al: Orphan nuclear receptor Nur77 translocates to mitochondria in the early phase of apoptosis induced by synthetic chenodeoxycholic acid derivatives in human stomach cancer cell line SNU-1. Ann NY Acad Sci 1010: 171-177, 2003.
38. Suh H, Jung EJ, Kim TH, Lee HY, Park YH and Kim KW: Anti-angiogenic activity of ursodeoxycholic acid and its derivatives. Cancer Lett 113: 117-122, 1997.
39. Im E, Choi SH, Suh H, Choi YH, Yoo YH and Kim ND: Synthetic bile acid derivatives induce apoptosis through a c-Jun N-terminal kinase and NF kappaB-dependent process in human cervical carcinoma cells. Cancer Lett 229: 49-57, 2005.
40. Drexler HC, Risau W and Konerding MA: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 14: 65-77, 2000.
41. Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6: 303-313, 1999.
42. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM and Osborne BA: Proteasomes play an essential role in thymocyte apoptosis. EMBO J 15: 3835-3844, 1996.
43. Li B and Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97: 3850-3855, 2000.
44. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M and Dang CV: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58: 4342-4348, 1998.
45. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
46. Chandra J, Niemer I, Gilbreath J, et al: Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92: 4220-4229, 1998.
47. Delic J, Masdehors P, Omura S, et al: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radio-resistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 77: 1103-1107, 1998.
48. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C and Pelicci PG: Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood 93: 1477-1481, 1999.